Cervix uteri ranks 8th globally with 662,301 new cases worldwide. Incidence rate is 14.1 times higher than average worldwide. Eswatini has highest incidence rate at 95.9%
Pap test detects precancerous and cancerous processes in cervix. Invented by Greek physician Georgios Papanikolaou in 1920s. Simplified version introduced by Canadian obstetrician Anna Marion Hilliard in 1957
Most common female genital tract tumor in Western countries. Type I (80-85%) is estrogen-dependent, type II (10-15%) is aggressive. MRI best assesses myometrial invasion and cervical involvement. FIGO staging correlates with prognosis and treatment planning
Cervical cancer is abnormal cell growth in cervix lining. Squamous cell carcinoma accounts for 70% of cases. Average age at diagnosis is 50 years old. Incidence has decreased since 1991 screening program
USPSTF guidelines replace ACOG's 2016 Practice Bulletin No. 168. Screening should begin at age 21 years. Three screening options available for ages 30-65: hrHPV testing, cytology, or co-testing. Primary hrHPV testing recommended for ages 25-65
Pap smear checks for cervical cancer and cell changes. Test collects cells from cervix to detect cancer. Named after Greek doctor Georgios Papanikolaou